SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Mar 20, 2025
– Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 –
Read more at globenewswire.com
